Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04580979 · ClinicalTrials.gov registry record
Natural History Study of FDXR Mutation-related Mitochondriopathy
A clinical trial, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- 33
- Enrollment target
NCT04580979 is a clinical trial that has completed, run by State University of New York at Buffalo. The registered enrollment target is 33 participants.
The verdict
NCT04580979 has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
The purpose of the study is to systematically characterize the clinical course of the progressive neuropathy and optic atrophy observe in pediatric and adult patients with biallelic mutations in the ferredoxin reductase gene.
Interventions
- GENETIC Mutation analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2020-11-03 |
| Est. Completion | 2023-08-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04580979
The ClinicalTrials.gov registry entry for NCT04580979 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mutation analysis is the first listed.
NCT04580979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04580979 about?
NCT04580979 is a clinical study titled "Natural History Study of FDXR Mutation-related Mitochondriopathy". The purpose of the study is to systematically characterize the clinical course of the progressive neuropathy and optic atrophy observe in pediatric and adult patients with biallelic mutations in the ferredoxin reductase gene.
What is the current status of trial NCT04580979?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2020-11-03. Estimated completion is 2023-08-17.
What interventions are being tested in trial NCT04580979?
The interventions under investigation include: Mutation analysis (GENETIC).
Who is sponsoring clinical trial NCT04580979?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.